Introduction: Uveal melanoma.
D000284:Administration, Oral; D000818:Animals; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D009362:Neoplasm Metastasis / Q000517:prevention & control; D011034:Podophyllotoxin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011379:Prognosis; D019859:Proto-Oncogene Proteins c-met / Q000378:metabolism*; D017526:Receptor, IGF Type 1 / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D014604:Uveal Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D042461:Vascular Endothelial Growth Factor A; C415032:picropodophyllin; D019859:Proto-Oncogene Proteins c-met; D017526:Receptor, IGF Type 1; D011034:Podophyllotoxin